CYP3A4 and breast cancer: We measured the association between pharmaceutical inhibition of CYP2D6, CYP2C19, and CYP3A4 and recurrence in a large cohort of tamoxifen‐treated Danish premenopausal breast cancer patients using a Bayesian joint modeling approach and compared this with traditional Cox regression models.